We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sodium–glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology.
- Authors
Gangat, Naseema; Tefferi, Ayalew
- Abstract
This article discusses the use of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in the treatment of diabetes mellitus, heart failure, and chronic renal disease. It highlights the potential side effect of SGLT2i-induced erythrocytosis, which is an increase in red blood cell count and hemoglobin levels. The article explores the mechanisms behind this side effect, including increased erythropoietin production and suppression of hepcidin. It also discusses the potential benefits of SGLT2is in enhancing erythropoiesis and ameliorating anemia in patients with chronic kidney disease. The article emphasizes the importance of distinguishing between secondary and clonal causes of erythrocytosis and provides diagnostic considerations for healthcare professionals. Overall, the article suggests that SGLT2i-induced erythrocytosis is generally benign and reversible, but caution should be exercised in patients with underlying myeloproliferative neoplasms.
- Subjects
POLYCYTHEMIA; BLOOD cell count; MEDICAL personnel; RISK assessment; HEMATOLOGY; DAPAGLIFLOZIN; SODIUM-glucose cotransporters
- Publication
Nephrology Dialysis Transplantation, 2023, Vol 38, Issue 12, p2670
- ISSN
0931-0509
- Publication type
Article
- DOI
10.1093/ndt/gfad171